Back to Agenda
Parallel Session 6B: Clinical Trials
Session Chair(s)
Angelika Joos, MPharm
Executive Director, Global Regulatory Policy
MSD, Belgium
This session will discuss the evolution of the continental clinical trials landscape in Africa through AVAREF, provide insights into the revised ICH E6(R3) guidelines that is going to be adopted by end of 2024 and Clinical research opportunities in the Kingdom of Saudi Arabia. We will also host a panel discussion to hear more how the clinical trial frameworks are evolving in Egypt and Bahrain as well as some reflections from the pharmaceutical Industry.
Speaker(s)
Continental Clinical Trials
Rhanda Adechina
World Health Organization (WHO), Switzerland
Consultant AVAREF Secretariat
ICH E6/E8 revision update
Rebecca Stanbrook, RPh
Switzerland
EFPIA ICH E6(R3) Expert Working Group Member
The Experience from Saudi NIH
Halah Alenizi
Saudi National Institute of Health (Saudi NIH), Saudi Arabia
Clinical Trials Expert
The Experience from Saudi NIH
Abdulhadi M. Alqahtani
Saudi National Institute of Health (Saudi NIH), Saudi Arabia
Sr. Clinical Trial Specialist
Panel Discussion with QandA, with the additional participation of
Heba Khalil
Egyptian Drug Authority (EDA), Egypt
Head of GA of Clinical Trials
Panel Discussion with QandA, with the additional participation of
Sumaya Husain
National Health Regulatory Authority (NHRA), Bahrain
Clinical Trials Regulations Specialist
Panel Discussion with QandA, with the additional participation of
Mohei-Eldeen Hesham
AbbVie, Saudi Arabia
Evidence Generation Manager
Have an account?